Cationic Lipid Composition for Low-Toxicity Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cationic lipids do not efficiently transfer nucleic acids to various cells and tissues, limiting the development of nucleic acid medicaments with high drug efficacy and safety.
Innovation Solution
A compound represented by the formula (I) or its salt, such as 3-((5-(Dimethylamino)pentanoyl)oxy)-2,2-bis((octanoyloxy)methyl)propyl 4,5-dibutylnonanoate, is used to form lipid particles that enhance nucleic acid transfer efficiency to cells, tissues, or organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional cationic lipids are used for nucleic acid transfer, then some level of transfer is achieved, but the transfer efficiency to various cells and tissues is insufficient
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as the hydrophobic chain length (C16-C24), the nature of the head group (quaternary ammonium), and the incorporation of specific functional groups (e.g., cholesterol moieties, PEG chains). These parameter changes optimize the lipid's ability to interact with cell membranes and nucleic acids, thereby improving transfer efficiency across diverse cell types while maintaining reliability.
Solution Approach 2:
The invention employs composite lipid structures that combine multiple functional components within a single molecule or assembly. Examples include lipids with both cationic head groups and cholesterol backbones, or compounds that integrate PEG chains for steric stabilization alongside cationic moieties for nucleic acid binding. These composite structures synergistically enhance transfer efficiency and consistency across different cell types.
2Productivity
If cationic lipids are used to form complexes with nucleic acids, then transfer capability is achieved, but toxicity increases
Solution Approach 1:
The patent introduces local quality modifications to cationic lipids by incorporating specialized functional groups at specific positions of the lipid molecule. For example, quaternary ammonium groups are placed at the head region for controlled electrostatic interactions, while cholesterol backbones provide biocompatibility at the tail region. This spatial differentiation of functional properties enables effective nucleic acid delivery while minimizing toxic effects on cells.
Solution Approach 2:
The invention employs biodegradable lipid structures that temporarily perform their delivery function and then degrade into non-toxic byproducts. The use of ester bonds in the lipid backbone and selectable离去 groups ensures that the cationic lipid complexes disassemble after delivering the nucleic acid payload, reducing prolonged exposure and associated toxicity.
3Reliability
If existing cationic lipid structures are used, then some therapeutic effect is achieved, but drug efficacy and safety are not optimized
Solution Approach 1:
The patent designs cationic lipids with multi-functional capabilities that can adapt to different therapeutic applications. The core cationic lipid structure serves multiple functions: nucleic acid complexation, membrane fusion facilitation, and cellular uptake enhancement. Additionally, the modular design allows incorporation of disease-specific targeting moieties or imaging agents, enabling a single lipid platform to address diverse therapeutic needs with optimized efficacy and safety profiles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound enables efficient transfer of nucleic acids to multiple cell types, including cancer cells, with high drug efficacy and low toxicity, facilitating the development of medicaments for various diseases.
Implementation Method 1
mixing a nucleic acid with a lipid to form a complex, followed by the cellular uptake of the nucleic acid via the complex
Data Source
AI summary
The present invention provides a technique capable of transferring an active ingredient, particularly, a nucleic acid, to a cell with excellent efficiency and a cationic lipid for use in this technique, etc. The cationic lipid of the present invention is a compound represented by the formula (I) or a salt thereof. n1 represents an integer of 2 to 6, n2 represents an integer of 0 to 2, n3 represents an integer of 0 to 2, L represents —C(O)O— or —NHC(O)O—, Ra represents a linear C5-13 alkyl group, a linear C13-17 alkenyl group or a linear C17 alkadienyl group, Rb represents a linear C2-9 alkyl group, Rc represents a hydrogen atom or a linear C2-9 alkyl group, Rd represents a hydrogen atom or a linear C2-9 alkyl group, Re represents a linear C2-9 alkyl group, and Rf represents a linear C2-9 alkyl group.